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Abstract: Idiopathic generalized epilepsies are frequently encountered by neurologists, and 
providing an accurate diagnosis and effective treatment(s) are the necessary components of 
successful patient care. With the introduction of new antiepileptic medications, physicians are 
better equipped for this goal. The immediate-release formulation of lamotrigine (LTG-IR) has 
been approved for primary generalized tonic-clonic seizures since 2006. The extended-release 
formulation of lamotrigine (LTG-XR) was approved for adjunctive therapy in patients with 
primary generalized tonic-clonic seizures in 2010. Although its exact mechanism of action is 
not yet fully elucidated, studies have demonstrated multiple possible pathways. Although both 
the LTG-IR and LTG-XR formulations have similar side effects and are generally well toler-
ated, LTG-XR may be preferable for its ease of use, which may increase patient compliance and 
decrease fluctuations in serum drug levels. The ease of conversion between the formulations also 
makes lamotrigine an attractive treatment option for patients with primary generalized tonic-
clonic seizures. LTG-IR has demonstrated efficacy in treatment-resistant idiopathic generalized 
epilepsies in both adults and children.  Although there are still some questions regarding all 
possible applications of LTG-XR, as further research is being done, it is clear that LTG-XR 
may hold some advantages when compared with other anticonvulsants.
Keywords: lamotrigine, GTC, IGE, generalized seizures, treatment
Introduction
Seizures in idiopathic generalized epilepsies are “conceptualized as originating at 
some point within, and rapidly engaging, bilaterally distributed networks. Such bilat-
eral networks can include cortical and subcortical structures, but do not necessarily 
include the entire cortex”.1–3
Patients with idiopathic generalized epilepsies may experience one or more seizure 
types, ie, primary generalized tonic-clonic seizures, absence seizures, and myoclonic 
seizures.4 Primary generalized tonic-clonic seizures are the most common generalized 
seizure type and the one that is the easiest to monitor clinically. In the initial, tonic 
phase, patients experience muscle contraction and body stiffening, which is followed 
by a clonic phase of rhythmic jerking of the face and limbs. Although primary general-
ized tonic-clonic seizures are the most visually recognizable seizures, other types exist 
and must be considered in the selection of appropriate treatments. Absence seizures 
usually manifest as brief episodes of altered consciousness, often with staring; they 
may occur multiple times per hour and are associated with the classic electroencepha-
lographic (EEG) finding of generalized 3–4 Hz spike and wave discharges. Finally, 





or myoclonus that involves jerky movements of the body, 
sometimes affecting only one location, such as a single limb. 
Myoclonic seizures occur usually in patients with juvenile 
myoclonic epilepsy.
A recently published expert consensus statement sug-
gested valproate, lamotrigine, and topiramate as the initial 
monotherapy choices for patients with primary generalized 
tonic-clonic seizures.5 Since then, double-blind studies have 
further documented the efficacy of levetiracetam in the treat-
ment of idiopathic generalized epilepsy.6,7 Other idiopathic 
generalized epilepsy treatments may include zonisamide 
or vagus nerve stimulation.5,8–10 Overall, these treatments 
afford seizure freedom to approximately 80% of patients with 
idiopathic generalized epilepsies.11 Although lamotrigine is 
used for the treatment of all seizure types in patients with 
idiopathic generalized epilepsies, this review will focus on 
the use of lamotrigine in the treatment of primary general-
ized tonic-clonic seizures rather than myoclonic or absence 
seizures.
The mechanism of action of lamotrigine is not entirely 
elucidated. Studies have shown that it has multiple mecha-
nisms of action, including blockage of voltage-gated 
Na+ channels in the presynaptic neuronal membrane, stabi-
lizing membranes, and inhibiting neurotransmitter release, 
principally glutamate.12 Lamotrigine is also thought to act 
on the presynaptic membrane via N-type Ca+2   channel 
  inhibition.13 Furthermore, studies have suggested that lam-
otrigine exerts an antiepileptic effect by acting upon the post-
synaptic   neuronal membrane via suppression of postsynaptic 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) receptors.14 Although studies provide evidence for 
various drug targets, lamotrigine is one of many medications 
that are utilized for their clinical efficacy without a fully 
elucidated mechanism of action.
The average elimination half-life of immediate-release 
lamotrigine (LTG-IR) is approximately 24 hours when used 
in monotherapy. However, there is a sizeable variation in 
metabolism among individual patients that may produce 
large interindividual variations in levels.15 Furthermore, 
the elimination half-life of lamotrigine varies depending 
on coadministered medications, and the interactions with 
enzyme-inducing antiepileptic drugs or valproate are the 
most widely recognized. To attenuate such variations in serum 
concentration and to reduce the risk of both subtherapeutic 
and toxic serum levels, an enteric-coated extended-release 
formulation of lamotrigine (LTG-XR) was developed. 
LTG-XR has a modified-release eroding matrix to control 
its dissolution rate,16 which leads to changes in absorption 
rates (time to peak plasma concentration [Tmax] 1–1.5 hours 
for LTG-IR versus 4–11 hours for LTG-XR).17 Despite the 
changes in Tmax, the bioavailability of LTG-XR and LTG-IR 
is similar, except for patients taking enzyme-inducing antiepi-
leptic drugs in whom the bioavailability of LTG-XR is 21% 
lower; the clinical importance of this finding is not clear.17 Its 
levels have been shown to be unaffected by high-fat meals, 
suggesting that the LTG-XR form is not significantly lipo-
philic.18 Studies have shown that lamotrigine is eliminated 
via hepatic N2-glucuronidation.19
LTG-XR may be preferable to LTG-IR for several rea-
sons. Most obviously, the less frequent dosing of LTG-XR 
may enhance patient compliance and therefore provide better 
seizure control. For example, it is known that compliance 
decreases from 79% to 69% with once-daily versus twice-
daily medication dosing.20 In one study, 71% of epilepsy 
patients reported missing at least one dose of medication, 
which precipitated seizure(s) in 45% of cases.21   Furthermore, 
based on a pharmacokinetic model, delayed dosing of 
LTG-XR (as in, eg, missing the dose by up to 12 hours in a 
patient taking valproic acid or up to five hours in a patient 
taking enzyme-inducing antiepileptic drugs) has been pre-
dicted to yield clinically manageable fluctuations in serum 
concentration with a less than 20% drop in peak plasma con-
centration.22 As compared with LTG-IR, LTG-XR has been 
demonstrated to reduce fluctuations in daily trough-to-peak 
serum concentrations.17 Both formulations have similar side 
effect profiles, with the most adverse events being serious 
skin rashes and hypersensitivity reactions. Suicidal   ideation, 
acute organ failure, and blood dyscrasias have been reported 
with both formulations as serious adverse effects. Less severe, 
but more frequently observed, side effects for both formula-
tions of lamotrigine include   dizziness, tremor, vomiting, and 
diplopia.17,23 Headache, ataxia, blurred vision,   somnolence, 
and rhinitis have also been reported with the LTG-IR for-
mulation. Finally, both formulations carry the same drug 
interactions, including increased blood concentrations with 
the simultaneous use of valproic acid and decreased blood 
concentrations with concomitant use of carbamazepine, 
  phenytoin, phenobarbital, primidone, rifampin, or oral 
estrogen-containing contraceptives.
Because the LTG-XR formulation may be preferable in 
some cases as indicated above (eg, to improve compliance 
or to decrease the probability of seizures resulting from inad-
vertently missed doses), guidelines for successful conversion 
from LTG-IR to LTG-XR have been proposed. Studies have 
demonstrated that the conversion process is quite logical and 
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trough concentrations can be accomplished with equivalent 
daily milligrams of either formulation.17
LTG-IR was initially approved for the adjunctive treat-
ment of partial seizures in 1994. Four years later, it was 
approved as adjunctive therapy for Lennox-Gastaut syndrome 
and as monotherapy for the treatment of partial seizures. 
Further expanding its utility, it was approved for the adjunc-
tive treatment of primary generalized tonic-clonic seizures 
in 2006. LTG-XR was approved for adjunctive   treatment of 
partial seizures in 2009 and for the adjunctive treatment of 
primary generalized tonic-clonic seizures in 2010.  Although 
both LTG-IR and LTG-XR are approved for use as adjunctive 
treatment of partial seizures and primary generalized tonic-
clonic seizures, LTG-IR has been approved for a wider age 
range, starting with patients at the age of two years, whereas 
LTG-XR is only approved for those over 13 years of age. 
Finally, LTG-IR is approved for monotherapy in primary 
generalized tonic-clonic seizures, whereas LTG-XR does 
not have such an approval.
Lamotrigine in clinical studies
Randomized controlled trials
Several randomized controlled studies of lamotrigine efficacy 
have been conducted. This review presents the data regarding 
the efficacy of lamotrigine in primary generalized tonic-
clonic seizures, with a special focus on the use of LTG-XR. 
Therefore, we will first review the studies that have led to 
LTG-IR/-XR approval for the treatment of primary general-
ized tonic-clonic seizures followed by other studies.
Immediate-release lamotrigine
One of the first reports on the use of LTG-IR in idiopathic 
generalized epilepsy examined its efficacy in patients with 
treatment-resistant seizures using a double-blind, placebo-
controlled, crossover design. Overall, 50% of the patients had 
at least 50% reduction in primary generalized tonic-clonic 
seizures and 33% had 50% or more reduction in absence 
seizures when compared with placebo. Use of LTG-IR led 
to a statistically significant decrease in primary   generalized 
tonic-clonic (P = 0.003) and absence seizures (P , 0.001), 
with 23/26 patients later continuing in an open-label 
study.24 In a regulatory, double-blinded study, 117 patients 
aged 2–55 years with idiopathic generalized epilepsies and 
experiencing medication-refractory primary generalized 
tonic-clonic seizures were randomized to receive LTG-IR or 
placebo. In the combined escalation and maintenance phases, 
the median percent reduction in generalized seizures was 
66.5% with LTG-IR versus 34.2% with placebo (P = 0.006). 
These numbers were slightly lower in the escalation phase 
(60.6% versus 32.8%; P = 0.038) and higher in the mainte-
nance phase (81.9% versus 43.0%; P = 0.006).25 Furthermore, 
approximately 72% of LTG-IR patients were considered 
responders compared with 49% of patients receiving placebo 
(P = 0.014). A similar pattern of results was observed for all 
generalized seizures. Post hoc analysis of these data revealed 
that LTG-IR was superior to placebo in median days to third, 
sixth, ninth, and 12th seizure (P , 0.022 for all),26 with its 
efficacy evident within the first two weeks of therapy initia-
tion (when compared with placebo, P = 0.036).27 The data 
from the original trial were later reanalyzed with a focus on 
the pediatric population.28 This analysis included 45 chil-
dren and adolescents, aged 2–19 years, who were randomly 
assigned to receive either LTG-IR or placebo. A significant 
decrease in median generalized seizure frequency between 
the groups was noted (77% versus 40%; P = 0.044), with 
median primary generalized tonic-clonic seizure counts per 
month of 0.4 versus 2.5 during the entire treatment period 
(P = 0.007), and higher treatment success in the escalation 
phase (0.7 versus 3.6; P = 0.008) than in the maintenance 
phase (0.3 versus 2.0; P = 0.005). Based on these studies, 
LTG-IR was deemed efficacious for the treatment of primary 
generalized tonic-clonic seizures in children and adults.
Extended-release lamotrigine
Although there is evidence for the efficacy of LTG-IR for 
the treatment of primary generalized tonic-clonic seizures, 
the arrival of the LTG-XR formulation necessitated new 
efficacy and tolerability studies. In a randomized, double-
blind trial of LTG-XR in patients with primary generalized 
tonic-clonic seizures, a pragmatic intent-to-treat analysis 
was used to compare the efficacy of LTG-XR (n = 70) with 
placebo (n = 73). The seizure-free rate was 44% versus 12% 
(P , 0.0001), and the responder rate for 50% reduction in 
seizure frequency during the maintenance phase was 70% 
versus 38% (P = 0.0002).29 Another randomized, double-
blind, placebo-controlled, parallel-group trial assessed the 
efficacy of LTG-XR in lamotrigine-naïve patients aged 
13 years and over with primary generalized tonic-clonic 
seizures. The study compared 153 patients who were random-
ized to LTG-XR (n = 76) with placebo (n = 77). Although 
the primary generalized tonic-clonic seizure frequencies per 
week at baseline were similar between the LTG-XR (0.8) 
and placebo (0.6) groups, the median percent decrease from 
baseline during the escalation phase was 62% for LTG-XR 
versus 26% for placebo (P = 0.0003), and 89% for LTG-XR 





phase. The decrease in seizure frequency related to LTG-XR 
administration was 76% versus 30% in the placebo group 
(P , 0.0001). Notably, this study also addressed the rate of 
seizure freedom with extended-release adjunctive therapy. 
The rate of seizure freedom in the escalation phase was 23% 
and 11% in the respective groups (P = 0.075), and during the 
maintenance phase the rate of seizure freedom was 46.4% 
and 14.3% for the extended-release and placebo groups 
(P = 0.034), respectively.30
Other immediate-release 
lamotrigine studies
LTG-IR appears to be of comparable efficacy with another 
first-line antiepileptic drug, valproate, when treating newly 
diagnosed individuals with generalized epilepsies.31 In the 
open-label LAM-SAFE study, patients with new-onset epi-
lepsy were stratified to either a carbamazepine–lamotrigine 
arm (patients with focal onset seizures) or to a valproate–
lamotrigine arm (patients with idiopathic generalized epi-
lepsy). In the idiopathic generalized epilepsy (second) arm, 
63 patients received either valproate (n = 30) or lamotrigine 
(n = 33). During the 24 weeks of study participation, 61% 
of the lamotrigine patients and 84% of the valproate patients 
became seizure-free (difference not significant).32 Another 
controlled trial in patients with generalized onset or unclassi-
fied seizures compared the efficacy of valproate, LTG-IR, and 
topiramate.33 In this study, patients were randomly assigned to 
valproate, LTG-IR, or topiramate and followed up for several 
years after therapy initiation. In all enrolled patients, time 
to treatment failure for valproate was greater than for topi-
ramate, ie, hazard ratio (HR) 1.57, 95% confidence interval 
(CI) 1.19–2.08, but there was no difference between valproate 
and LTG-IR (HR 1.25, 95% CI 0.94–1.68). When the same 
analysis was conducted in patients with definite idiopathic 
generalized epilepsy, valproate was significantly better than 
both LTG-IR (HR 1.55, 95% CI 1.07–2.24) and topiramate 
(HR 1.89, 95% CI 1.32–2.70). Furthermore, for time to 
12-month remission, valproate was significantly better than 
LTG-IR overall (HR 0.76, 95% CI 0.62–0.94) and for the 
idiopathic generalized epilepsy patients (HR 0.68, 95% CI 
0.53–0.89). There was no difference between valproate and 
topiramate in either the analysis overall or for the subgroup 
with idiopathic   generalized epilepsy.
A prospective, open-label, video-EEG study examined the 
efficacy of LTG-IR as an add-on or monotherapy in idiopathic 
generalized epilepsy.34 Of the 47 patients enrolled, 12 had 
childhood absence epilepsy (nine became seizure-free), 
12 had juvenile absence epilepsy (10 became seizure-free), 
and 15 had juvenile myoclonic epilepsy (seven became 
seizure-free). The remaining patients had various other 
idiopathic generalized epilepsy syndromes, including grand 
mal on awakening; seizure-free status was less frequent in 
these patients.
In a retrospective study, the efficacy of LTG-IR was 
compared with the efficacy of valproate in patients with 
idiopathic generalized epilepsy.35 More patients remained 
on valproate monotherapy at one and two years (89% and 
83%, respectively) than on lamotrigine monotherapy (69% 
and 57%). Although valproate showed comparable efficacy 
in all idiopathic generalized epilepsy syndromes, lamotrigine 
appeared to be more efficacious in patients with childhood 
and juvenile absence epilepsies than in juvenile myoclonic 
epilepsy.35 This is consistent with previous reports of lam-
otrigine potentially aggravating myoclonic epilepsies.36,37
Because valproic acid has traditionally been a first-line 
antiepileptic drug in the treatment of juvenile myoclonic 
epilepsy, several studies have compared LTG-IR with val-
proate for the treatment of this disorder. In one open-label 
study, patients aged $12 years with newly diagnosed juvenile 
myoclonic epilepsy (drug-naïve or on an incorrect antiepi-
leptic drug due to misdiagnosis) were enrolled.38 LTG-IR 
was titrated up to a maximum dosage of 100–500 mg/day, 
followed by a 24-week treatment phase with LTG-IR adjust-
ments as needed. Of the 29 analyzable patients, 58% experi-
enced a reduction from baseline seizure frequency of at least 
50% in days with myoclonus, and 56% and 38% of patients 
experienced a reduction of at least 50% in the frequency 
of primary generalized tonic-clonic and absence seizures, 
respectively. LTG-IR was also used in an open-label study 
of juvenile myoclonic epilepsy patients who had failed treat-
ment with valproate.39 Investigators found that 50% of the 63 
enrolled patients had a reduction in adverse events as a result 
of the change in anticonvulsants, and 67% had improvement 
in global clinical status; 76% of patients rated LTG-IR better 
than valproate. Another study retrospectively evaluated the 
efficacy of LTG-IR in monotherapy for a variety of pediatric 
epilepsies, including idiopathic generalized epilepsy. Of the 
83 children enrolled, 32 had idiopathic generalized epilepsy, 
and 36% of them became seizure-free on LTG-IR, includ-
ing all children with the diagnosis of juvenile myoclonic 
epilepsy.40 Buchanan evaluated 12 patients with juvenile 
myoclonic epilepsy who had either failed valproate or refused 
to take it; five patients became seizure-free after LTG-IR was 
introduced.41 In another study, absence seizures were com-
pletely eliminated in refractory cases while using LTG-IR 




Lamotrigine for generalized tonic-clonic seizures
study, all of the patients with juvenile myoclonic epilepsy 
experienced complete seizure freedom when using LTG-IR in 
combination therapy. In a pilot study, Timmings and Richens 
evaluated the efficacy of LTG-IR as second-line monotherapy 
in 17 patients with juvenile myoclonic   epilepsy.43 They 
showed that there were no differences in seizure control fol-
lowing a four-week, single-blind, placebo add-on period, nor 
were there differences in a later randomization to continued 
therapy with valproate or a switch to LTG-IR in a double-
dummy, double-blind, 12-week study.
In a longitudinal study of 10 years, lamotrigine was 
administered to patients with medication-resistant idiopathic 
generalized epilepsy.44 The authors observed that 33% of 
patients became seizure-free, and 43.6% had improvement 
in seizure control; 23% dropped out of the study due to 
insufficient seizure control, and 17.9% experienced adverse 
effects that necessitated medication cessation. Meo et al 
reported a similar magnitude of seizure reduction rates with 
better tolerability.45
Although LTG-XR is approved by the US Food and Drug 
Administration as adjunctive therapy for both partial and 
primary generalized tonic-clonic seizures, its indication for 
myoclonic and absence seizures is not yet in place. However, 
if the success with LTG-IR in the treatment of idiopathic 
generalized epilepsy may be extrapolated to LTG-XR, 
  studies showing its efficacy in the treatment of myoclonic 
and absence seizures are likely to be imminent.
Conclusions
LTG-IR and LTG-XR have provided a novel treatment option 
for patients with epilepsy, a disease that has multiple comor-
bidities and is potentially threatening to quality of life.46 
A medication such as lamotrigine that is useful for application 
in multiple forms of epilepsy is especially advantageous. The 
efficacy that has been attained in clinical studies, as well as 
its superior tolerability profile, makes lamotrigine an impor-
tant antiepileptic drug choice. More research is required to 
elucidate all possible indications for LTG-XR use. Some 
controversy still exists regarding its efficacy, particularly in 
the treatment of myoclonic seizures in juvenile myoclonic 
epilepsy, and therefore further studies are needed.
In the published studies, lamotrigine has rarely produced 
severe adverse reactions, although the risk of life-threatening 
rash must not be ignored. Generally, this is a well toler-
ated antiepileptic drug, with the most common side effects 
including headache, nausea, and dizziness. These are, at 
least in part, dose-related, and may be endurable in many 
cases. Lamotrigine is also easily managed, with relatively 
few drug interactions, as compared with some of the older 
antiepileptic drugs.
The straightforward conversion between LTG-IR and 
LTG-XR dosing is also advantageous. A more manageable 
dosing regimen, enhancing patient compliance and with 
steadier serum concentrations, makes LTG-XR an attractive 
option. The LTG-XR formulation appears to have a similar 
degree of efficacy to and comparable tolerability profile with 
that of LTG-IR. Further research is still necessary in order to 
generate approval by the Food and Drug Administration for all 
potential applications of LTG-XR. However, these advance-
ments are generating hope in those affected by epilepsy.
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